Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Xenetic Biosciences Q2 EPS $(0.45) Beats $(0.65) Estimate, Sales $589.897K Miss $720.000K Estimate

Author: Benzinga Newsdesk | August 13, 2025 07:09am
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.65) by 30.77 percent. This is a 45.78 percent increase over losses of $(0.83) per share from the same period last year. The company reported quarterly sales of $589.897 thousand which missed the analyst consensus estimate of $720.000 thousand by 18.07 percent. This is a 18.79 percent decrease over sales of $726.404 thousand the same period last year.

Posted In: XBIO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist